Format
Items per page
Sort by

Send to:

Choose Destination

Results: 20

1.

Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity.

Budimir N, Huckriede A, Meijerhof T, Boon L, Gostick E, Price DA, Wilschut J, de Haan A.

PLoS One. 2012;7(1):e30898. doi: 10.1371/journal.pone.0030898. Epub 2012 Jan 27.

2.

Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection.

Schmitz N, Beerli RR, Bauer M, Jegerlehner A, Dietmeier K, Maudrich M, Pumpens P, Saudan P, Bachmann MF.

Eur J Immunol. 2012 Apr;42(4):863-9. doi: 10.1002/eji.201041225.

PMID:
22531913
3.

Inflammatory responses to trivalent influenza virus vaccine among pregnant women.

Christian LM, Iams JD, Porter K, Glaser R.

Vaccine. 2011 Nov 8;29(48):8982-7. doi: 10.1016/j.vaccine.2011.09.039. Epub 2011 Sep 22.

4.
5.

A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.

Wu CY, Yeh YC, Chan JT, Yang YC, Yang JR, Liu MT, Wu HS, Hsiao PW.

PLoS One. 2012;7(8):e42363. doi: 10.1371/journal.pone.0042363. Epub 2012 Aug 7.

6.

Virus-like particle (VLP)-based vaccines for pandemic influenza: performance of a VLP vaccine during the 2009 influenza pandemic.

López-Macías C.

Hum Vaccin Immunother. 2012 Mar;8(3):411-4. doi: 10.4161/hv.18757. Epub 2012 Feb 14. Review.

7.

Effect of prednisone on response to influenza virus vaccine in asthmatic children.

Fairchok MP, Trementozzi DP, Carter PS, Regnery HL, Carter ER.

Arch Pediatr Adolesc Med. 1998 Dec;152(12):1191-5.

PMID:
9856428
8.

Influenza virus vaccine based on the conserved hemagglutinin stalk domain.

Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, García-Sastre A, Palese P.

MBio. 2010 May 18;1(1). pii: e00018-10. doi: 10.1128/mBio.00018-10.

9.

Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v).

Skowronski DM, Janjua NZ, De Serres G, Purych D, Gilca V, Scheifele DW, Dionne M, Sabaiduc S, Gardy JL, Li G, Bastien N, Petric M, Boivin G, Li Y.

J Infect Dis. 2012 Dec 15;206(12):1852-61. doi: 10.1093/infdis/jis500. Epub 2012 Aug 7.

10.
11.

Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development.

Staneková Z, Varečková E.

Virol J. 2010 Nov 30;7:351. doi: 10.1186/1743-422X-7-351. Review.

12.

Increased risk of noninfluenza respiratory virus infections associated with receipt of inactivated influenza vaccine.

Cowling BJ, Fang VJ, Nishiura H, Chan KH, Ng S, Ip DK, Chiu SS, Leung GM, Peiris JS.

Clin Infect Dis. 2012 Jun;54(12):1778-83. doi: 10.1093/cid/cis307. Epub 2012 Mar 15.

13.

H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans.

Khurana S, Wu J, Verma N, Verma S, Raghunandan R, Manischewitz J, King LR, Kpamegan E, Pincus S, Smith G, Glenn G, Golding H.

J Virol. 2011 Nov;85(21):10945-54. doi: 10.1128/JVI.05406-11. Epub 2011 Aug 24.

14.

Seasonal trivalent inactivated influenza vaccine protects against 1918 Spanish influenza virus infection in ferrets.

Pearce MB, Belser JA, Gustin KM, Pappas C, Houser KV, Sun X, Maines TR, Pantin-Jackwood MJ, Katz JM, Tumpey TM.

J Virol. 2012 Jul;86(13):7118-25. doi: 10.1128/JVI.00674-12. Epub 2012 May 2.

15.

Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010.

WHO Writing Group, Ampofo WK, Baylor N, Cobey S, Cox NJ, Daves S, Edwards S, Ferguson N, Grohmann G, Hay A, Katz J, Kullabutr K, Lambert L, Levandowski R, Mishra AC, Monto A, Siqueira M, Tashiro M, Waddell AL, Wairagkar N, Wood J, Zambon M, Zhang W.

Influenza Other Respir Viruses. 2012 Mar;6(2):142-52, e1-5. doi: 10.1111/j.1750-2659.2011.00277.x. Epub 2011 Aug 8.

PMID:
21819547
16.

Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus.

Tan M, Jiang X.

Nanomedicine (Lond). 2012 Jun;7(6):889-97. doi: 10.2217/nnm.12.62. Review.

17.

Structure of the influenza virus A H5N1 nucleoprotein: implications for RNA binding, oligomerization, and vaccine design.

Ng AK, Zhang H, Tan K, Li Z, Liu JH, Chan PK, Li SM, Chan WY, Au SW, Joachimiak A, Walz T, Wang JH, Shaw PC.

FASEB J. 2008 Oct;22(10):3638-47. doi: 10.1096/fj.08-112110. Epub 2008 Jul 9.

18.

The contribution of systemic and pulmonary immune effectors to vaccine-induced protection from H5N1 influenza virus infection.

Lau YF, Wright AR, Subbarao K.

J Virol. 2012 May;86(9):5089-98. doi: 10.1128/JVI.07205-11. Epub 2012 Feb 29.

19.

A replication-incompetent PB2-knockout influenza A virus vaccine vector.

Victor ST, Watanabe S, Katsura H, Ozawa M, Kawaoka Y.

J Virol. 2012 Apr;86(8):4123-8. doi: 10.1128/JVI.06232-11. Epub 2012 Feb 1.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk